UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934
(AMENDMENT NO. 15)*

THE COOPER COMPANIES, INC.
- ---
(Name of Issuer)

Common Stock, par value $.10 per share
- ---
(Title of Class of Securities)

216648402
- ---
(CUSIP Number)

Harold L. Schneider, Esq.
Tenzer Greenblatt LLP
405 Lexington Avenue, New York, New York 10174 (212) 573-4348
- ---
(Name, Address and Telephone Number of Person Authorized to Receive Notice
and Communications)

November 17, 1997
- ---
(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report
the acquisition which is the subject of this Schedule 13D, and is filing this
schedule because of Rule 13d-1(b)(3) or (4), check the following box [ ].

Check the following box if a fee is being paid with the statement [ ]. (A fee is
not required only if the reporting person: (1) has a previous statement on file
reporting beneficial ownership of more than five percent of the class of
securities described in Item 1; and (2) has filed no amendment subsequent
thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).

NOTE: Six copies of this statement, including all exhibits, should be filed with
the Commission. See Rule 13d-1(a) for other parties to whom copies are to be
sent.

* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter
disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).

```
- ----------------------------------------------------------------------------------------------------
1         NAME OF REPORTING PERSON
          S.S OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

          Cooper Life Sciences, Inc.
          94-2563513
- ----------------------------------------------------------------------------------------------------
2         CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*                           (a) [ ]
                                                                                      (b) [ ]
- ----------------------------------------------------------------------------------------------------
3         SEC USE ONLY
- ----------------------------------------------------------------------------------------------------
4         SOURCE OF FUNDS*

          Not Applicable
- ----------------------------------------------------------------------------------------------------
5         CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e)    [ ]

- ----------------------------------------------------------------------------------------------------
6         CITIZENSHIP OR PLACE OF ORGANIZATION

          Delaware
- ----------------------------------------------------------------------------------------------------
                 7    SOLE VOTING POWER
 NUMBER OF            492,133 shares of Common Stock
   SHARES        -----------------------------------------------------------------------------------
BENEFICIALLY     8    SHARED VOTING POWER
 OWNED BY             -0-
   EACH          -----------------------------------------------------------------------------------
REPORTING        9    SOLE DISPOSITIVE POWER
 PERSON              492,133 shares of Common Stock
  WITH           -----------------------------------------------------------------------------------
                 10   SHARED DISPOSITIVE POWER
                      -0-
- ----------------------------------------------------------------------------------------------------
11        AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

          492,133 shares of Common Stock
- ----------------------------------------------------------------------------------------------------
12        CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*            [ ]

- ----------------------------------------------------------------------------------------------------
13        PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

          3.33%
- ----------------------------------------------------------------------------------------------------
14        TYPE OF REPORTING PERSON*

          CO
- ----------------------------------------------------------------------------------------------------


                     *SEE INSTRUCTIONS BEFORE FILLING OUT!
```

This Amendment No. 15 amends and supplements Item 5 of the Schedule 13D filed with the Securities and Exchange Commission on June 22, 1992, as amended by Amendment No. 1 dated November 12, 1992, Amendment No. 2 dated July 6, 1993, Amendment No. 3 dated August 24, 1993, Amendment No. 4 dated July 14, 1994, Amendment No. 5 dated August 15, 1994, Amendment No. 6 dated September 6, 1994, Amendment No. 7 dated March 7, 1995, Amendment No. 8 dated August 27, 1996, Amendment No. 9 dated December 12, 1996, Amendment No. 10 dated February 10, 1997, Amendment No. 11 dated February 21, 1997, Amendment No. 12 dated March 6, 1997, Amendment No. 13 dated July 11, 1997 and Amendment No. 14 dated October 31, 1997 (as amended, the "Schedule 13D"), by Cooper Life Sciences, Inc., a Delaware corporation ("CLS"), relating to the Common Stock, par value $.10 per share (the "Common Stock") of The Cooper Companies, Inc., a Delaware corporation (the "Company"). Except as modified hereby, there has been no change in the information previously reported in the Schedule 13D.

Item 5.   Interest in Securities of Issuer.

                 The number of shares of Common Stock which may be deemed to be
                 beneficially owned by CLS has decreased by more than 1% of the
                 number of shares of the class which are deemed to be outstanding.
                 Said decrease is the result of open market sales of an aggregate
                 of 501,300 shares of Common Stock, as more fully set forth on
                 Schedule I hereto.

SIGNATURE

After reasonable inquiry, and to the best of my knowledge and
belief, I certify that the information set forth in this statement is true,
complete and correct.

COOPER LIFE SCIENCES, INC.

By: /s/ Steven Rosenberg
   _____
November 26, 1997   Name: Steven Rosenberg
- -----------------   Title: Vice President
   Date

SCHEDULE I
TO AMENDMENT NO. 15 TO SCHEDULE 13D

Nature of Transaction	Date	No. of Shares Sold	Price Per Share*
Sale	11/03/97	111,300	$37.1177
Sale	11/04/97	4,900	37.875
Sale	11/10/97	5,100	37.875
Sale	11/13/97	10,000	35.50
Sale	11/14/97	9,000	35.625
Sale	11/17/97	10,000	35.875
Sale	11/17/97	10,000	36.00
Sale	11/17/97	10,000	36.125
Sale	11/17/97	10,000	36.25
Sale	11/17/97	10,000	36.375
Sale	11/17/97	10,000	36.50
Sale	11/17/97	10,000	36.75
Sale	11/17/97	10,000	36.875
Sale	11/17/97	10,000	37.00
Sale	11/17/97	21,000	36.1667
Sale	11/18/97	10,000	37.125
Sale	11/18/97	10,000	37.25
Sale	11/18/97	10,000	37.375
Sale	11/18/97	10,000	37.50
Sale	11/18/97	10,000	37.625
Sale	11/18/97	10,000	37.75
Sale	11/18/97	10,000	37.875
Sale	11/18/97	10,000	38.00
Sale	11/18/97	10,000	38.125
Sale	11/18/97	10,000	38.25
Sale	11/18/97	10,000	38.375
Sale	11/18/97	10,000	38.50
Sale	11/18/97	10,000	38.625
Sale	11/18/97	10,000	38.75
Sale	11/19/97	10,000	38.875
Sale	11/19/97	10,000	39.00
Sale	11/19/97	10,000	39.125
Sale	11/19/97	10,000	39.25
Sale	11/19/97	10,000	39.38
Sale	11/19/97	10,000	39.50
Sale	11/19/97	10,000	39.625
Sale	11/20/97	10,000	39.75
Sale	11/20/97	10,000	39.875
Sale	11/20/97	10,000	40.00
Sale	11/20/97	10,000	40.125

TOTAL   501,300

- --------------------

* Before payment of commissions.